TABLE OF CONTENTS
1 INTRODUCTION 85
1.1 OBJECTIVES OF THE STUDY 85
1.2 MARKET DEFINITION 85
1.3 OVERVIEW OF THE GLOBAL SJS/TEN TREATMENT MARKET 85
1.4 LIMITATIONS 88
1.5 MARKETS COVERED 88
2 MARKET SEGMENTATION 93
2.1 MARKETS COVERED 93
2.2 GEOGRAPHICAL SCOPE 94
2.3 YEARS CONSIDERED FOR THE STUDY 95
2.4 CURRENCY AND PRICING 95
2.5 DBMR TRIPOD DATA VALIDATION MODEL 96
2.6 MULTIVARIATE MODELLING 99
2.7 TREATMENT LIFELINE CURVE 99
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 100
2.9 DBMR MARKET POSITION GRID 101
2.10 MARKET APPLICATION COVERAGE GRID 102
2.11 VENDOR SHARE ANALYSIS 103
2.12 SECONDARY SOURCES 104
2.13 ASSUMPTIONS 104
3 EXECUTIVE SUMMARY 105
4 PREMIUM INSIGHTS 108
4.1 KEY TRENDS 111
4.2 COST OF TREATMENT 112
4.3 KEY PLAYERS STRATEGIES 113
4.4 LONG TERM GROWTH APPROACH 114
5 EPIDEMIOLOGY 115
6 INDUSTRY INSIGHTS 119
6.1 PATENT ANALYSIS 119
6.2 DEMOGRAPHIC TRENDS 121
6.3 PATIENT FLOW DIAGRAM 122
6.4 KEY PRICING STRATEGIES 123
6.5 KEY PATIENT ENROLLMENT STRATEGIES 123
7 MARKET OVERVIEW 126
7.1 DRIVERS 128
7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 128
7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 129
7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 129
7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 130
7.2 RESTRAINTS 132
7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 132
7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 132
7.3 OPPORTUNITIES 133
7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 133
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 134
7.4 CHALLENGES 134
7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 134
7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 135
8 GLOBAL SJS/TEN TREATMENT MARKET, BY TREATMENT 136
8.1 OVERVIEW 137
8.2 MEDICATIONS 140
8.2.1 ANTIHISTAMINES 141
8.2.1.1 HYDROXYZINE 141
8.2.1.2 FEXOFENADINE 141
8.2.2 CORTICOSTEROID 142
8.2.2.1 DEXAMETHASONE 142
8.2.2.2 PREDNISOLONE 142
8.2.2.3 METHYLPREDNISOLONE 142
8.2.2.4 HYDROCORTISONE 142
8.2.2.5 OTHERS 142
8.2.3 ANTIBIOTICS 142
8.2.3.1 NAFCILLIN 143
8.2.3.2 GENTAMICIN 143
8.2.3.3 OTHERS 143
8.2.4 ANALGESICS 143
8.2.4.1 MORPHINE 143
8.2.4.2 FENTANYL CITRATE 144
8.2.4.3 OTHERS 144
8.2.5 ANTICOAGULANTS 144
8.2.6 ANTISEPTICS 144
8.2.6.1 CHLORHEXIDINE GLUCONATE 144
8.2.6.1.1 PERIOGARD 145
8.2.6.1.2 PERIDEX 145
8.2.6.1.3 AVAGARD 145
8.2.6.1.4 HIBICLENS 145
8.2.6.1.5 OTHERS 145
8.2.6.2 OCTENISEPT 145
8.2.6.3 POLYHEXANIDE SOLUTIONS 145
8.2.6.4 OTHERS 146
8.2.7 INTRAVENOUS IMMUNOGLOBULIN 146
8.2.8 CYCLOSPORINE 146
8.2.8.1 NEORAL 146
8.2.8.2 SANDIMMUNE 146
8.2.8.3 OTHERS 146
8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-)BLOCKING AGENT (ETANERCEPT) 146
8.2.10 OTHER TREATMENT 147
8.2.10.1 CYCLOPHOSPHAMIDE 147
8.2.10.2 N-ACETYLCYSTEINE 147
8.2.10.3 MONOCLONAL ANTIBODIES 147
8.2.10.4 THALIDOMIDE 147
8.3 SUPPORT CARE 147
8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 148
8.3.2 PAIN MANAGEMENT 149
8.3.2.1 LIDOCAINE 149
8.3.2.2 OTHERS 149
8.3.3 NUTRITION SUPPORT 149
8.3.4 ORAL CARE 149
8.3.5 PLASMAPHERESIS 149
8.3.6 BANDAGES 149
8.3.6.1 BIOLOGICAL DRESSING 150
8.3.6.1.1 ALLOGRAFT 150
8.3.6.1.2 XENOGRAFT 150
8.3.6.1.3 HOMOGRAFT 150
8.3.6.1.4 OTHERS 150
8.3.6.2 BIOSYNTHETIC DRESSING 151
8.3.6.3 SILVER IMPREGNATED DRESSING 151
8.4 HOSPITALIZATION 151
8.5 ISOLATION 152
8.6 OINTMENTS 152
8.6.1 BENZOCAINE 153
8.6.2 AMERICAINE 153
8.6.3 ANBESOL 153
8.6.4 CHIGGEREX PLUS 153
8.6.5 OTHERS 154
8.7 OTHERS 154
9 GLOBAL SJS/TEN TREATMENT MARKET, BY DIAGNOSIS 155
9.1 OVERVIEW 156
9.2 PHYSICAL EXAM 159
9.3 SKIN BIOPSY 159
9.4 MEDICAL HISTORY 160
9.5 BLOOD TEST 161
9.5.1 COMPLETE BLOOD COUNT 162
9.5.2 ERYTHROCYTE SEDIMENTATION RATE 162
9.5.3 COAGULATION STUDIES 162
9.5.4 UREA AND ELECTROLYTES 163
9.5.5 LIVER FUNCTION TEST 163
9.6 CULTURES 163
9.7 OTHERS 164
10 GLOBAL SJS/TEN TREATMENT MARKET, BY CAUSE 165
10.1 OVERVIEW 166
10.2 SPECIFIC TREATMENT 169
10.3 INFECTION 169
10.4 OTHERS 170
11 GLOBAL SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 171
11.1 OVERVIEW 172
11.2 ORAL 175
11.3 PARENTERAL 175
11.3.1 INTRAVENOUS 176
11.3.2 SUBCUTANEOUS 176
11.3.3 OTHERS 176
11.4 TOPICAL 176
11.4.1 OINTMENTS 177
11.4.2 SOLUTION 177
11.4.3 CREAMS 178
11.4.4 OTHERS 178
11.5 OTHERS 178
12 GLOBAL SJS/TEN TREATMENT MARKET, BY DRUG TYPE 179
12.1 OVERVIEW 180
12.2 BRANDED 183
12.2.1 NEORAL 184
12.2.2 SANDIMMUNE 184
12.2.3 VISTARIL 184
12.2.4 DURAMORPH 184
12.2.5 FENTORA 184
12.2.6 ENBREL 184
12.2.7 OTHERS 184
12.3 GENERIC 184
13 GLOBAL SJS/TEN TREATMENT MARKET, BY THERAPY TYPE 186
13.1 OVERVIEW 187
13.2 COMBINATION THERAPY 190
13.3 MONOTHERAPY 190
14 GLOBAL SJS/TEN TREATMENT MARKET, BY PATIENT TYPE 192
14.1 OVERVIEW 193
14.2 GERIATRIC 196
14.2.1 FEMALE 197
14.2.2 MALE 197
14.3 ADULT 197
14.3.1 FEMALE 198
14.3.2 MALE 198
14.4 PEDIATRIC 198
15 GLOBAL SJS/TEN TREATMENT MARKET, BY END USER 200
15.1 OVERVIEW 201
15.2 HOSPITALS 204
15.3 SPECIALTY CLINICS 204
15.4 AMBULATORY SURGICAL CENTER 205
15.5 HOMECARE SETTING 206
15.6 OTHERS 206
16 GLOBAL SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL 208
16.1 OVERVIEW 209
16.2 RETAIL PHARMACIES 212
16.2.1 HOSPITAL ASSOCIATED PHARMACIES 213
16.2.2 DRUG STORE 213
16.2.3 ONLINE PHARMACIES 213
16.3 DIRECT TENDERS 213
16.4 OTHERS 214
17 GLOBAL SJS/TEN TREATMENT MARKET, BY REGION 215
17.1 OVERVIEW 216
17.2 NORTH AMERICA 222
17.2.1 U.S. 236
17.2.2 CANADA 244
17.2.3 MEXICO 253
17.3 SOUTH AMERICA 262
17.3.1 BRAZIL 276
17.3.2 ARGENTINA 284
17.3.3 REST OF SOUTH AMERICA 292
17.4 EUROPE 293
17.4.1 GERMANY 310
17.4.2 FRANCE 321
17.4.3 U.K. 332
17.4.4 ITALY 343
17.4.5 SPAIN 353
17.4.6 RUSSIA 363
17.4.7 TURKEY 374
17.4.8 BELGIUM 384
17.4.9 DENMARK 394
17.4.10 NETHERLANDS 405
17.4.11 SWITZERLAND 415
17.4.12 SWEDEN 425
17.4.13 POLAND 435
17.4.14 NORWAY 444
17.4.15 FINLAND 453
17.4.16 REST OF EUROPE 462
17.5 ASIA-PACIFIC 463
17.5.1 CHINA 480
17.5.2 JAPAN 491
17.5.3 INDIA 502
17.5.4 SOUTH KOREA 513
17.5.5 AUSTRALIA 524
17.5.6 SINGAPORE 535
17.5.7 THAILAND 545
17.5.8 INDONESIA 556
17.5.9 PHILIPPINES 566
17.5.10 MALAYSIA 576
17.5.11 NEW ZEALAND 586
17.5.12 VIETNAM 597
17.5.13 TAIWAN 608
17.5.14 REST OF ASIA-PACIFIC 619
17.6 MIDDLE EAST AND AFRICA 620
17.6.1 SOUTH AFRICA 636
17.6.2 SAUDI ARABIA 647
17.6.3 BAHRAIN 658
17.6.4 U.A.E 669
17.6.5 KUWAIT 680
17.6.6 OMAN 690
17.6.7 QATAR 701
17.6.8 EGYPT 712
17.6.9 ISRAEL 722
17.6.10 REST OF MIDDLE EAST AND AFRICA 733
18 GLOBAL SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE 734
18.1 COMPANY SHARE ANALYSIS: GLOBAL 734
18.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 735
18.3 COMPANY SHARE ANALYSIS: NORTH AMERICA 736
18.4 COMPANY SHARE ANALYSIS: EUROPE 737
19 SWOT ANALYSIS 738
20 COMPANY PROFILE 739
20.1 PFIZER INC. 739
20.1.1 COMPANY SNAPSHOT 739
20.1.2 REVENUE ANALYSIS 739
20.1.3 COMPANY SHARE ANALYSIS 740
20.1.4 PRODUCT PORTFOLIO 740
20.1.5 RECENT DEVELOPMENT 740

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.